PDCD1 and pneumonitis: Firstly, we observed one patient dead from pneumonitis after 2 months' therapy of camrelizumab, which suggested that more active measures should be taken when the elderly patients received PD-1 inhibitors to attenuate the potential severe pneumonitis.